PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
EDIT vs. SPYI
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility

Correlation

The correlation between EDIT and SPYI is 0.34, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

EDIT vs. SPYI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Editas Medicine, Inc. (EDIT) and NEOS S&P 500 High Income ETF (SPYI). The values are adjusted to include any dividend payments, if applicable.

-100.00%-50.00%0.00%50.00%SeptemberOctoberNovemberDecember2025February
-90.87%
42.30%
EDIT
SPYI

Key characteristics

Sharpe Ratio

EDIT:

-1.04

SPYI:

1.94

Sortino Ratio

EDIT:

-2.39

SPYI:

2.57

Omega Ratio

EDIT:

0.74

SPYI:

1.40

Calmar Ratio

EDIT:

-0.82

SPYI:

2.92

Martin Ratio

EDIT:

-1.28

SPYI:

13.38

Ulcer Index

EDIT:

63.66%

SPYI:

1.44%

Daily Std Dev

EDIT:

78.10%

SPYI:

9.96%

Max Drawdown

EDIT:

-98.74%

SPYI:

-10.19%

Current Drawdown

EDIT:

-98.48%

SPYI:

0.00%

Returns By Period

In the year-to-date period, EDIT achieves a 8.66% return, which is significantly higher than SPYI's 3.77% return.


EDIT

YTD

8.66%

1M

13.11%

6M

-65.50%

1Y

-83.07%

5Y*

-44.90%

10Y*

N/A

SPYI

YTD

3.77%

1M

2.04%

6M

9.48%

1Y

18.38%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

EDIT vs. SPYI — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

EDIT
The Risk-Adjusted Performance Rank of EDIT is 44
Overall Rank
The Sharpe Ratio Rank of EDIT is 33
Sharpe Ratio Rank
The Sortino Ratio Rank of EDIT is 11
Sortino Ratio Rank
The Omega Ratio Rank of EDIT is 33
Omega Ratio Rank
The Calmar Ratio Rank of EDIT is 44
Calmar Ratio Rank
The Martin Ratio Rank of EDIT is 1111
Martin Ratio Rank

SPYI
The Risk-Adjusted Performance Rank of SPYI is 8080
Overall Rank
The Sharpe Ratio Rank of SPYI is 7878
Sharpe Ratio Rank
The Sortino Ratio Rank of SPYI is 7474
Sortino Ratio Rank
The Omega Ratio Rank of SPYI is 8484
Omega Ratio Rank
The Calmar Ratio Rank of SPYI is 7979
Calmar Ratio Rank
The Martin Ratio Rank of SPYI is 8686
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

EDIT vs. SPYI - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Editas Medicine, Inc. (EDIT) and NEOS S&P 500 High Income ETF (SPYI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for EDIT, currently valued at -1.04, compared to the broader market-2.000.002.004.00-1.041.94
The chart of Sortino ratio for EDIT, currently valued at -2.39, compared to the broader market-6.00-4.00-2.000.002.004.006.00-2.392.57
The chart of Omega ratio for EDIT, currently valued at 0.74, compared to the broader market0.501.001.502.000.741.40
The chart of Calmar ratio for EDIT, currently valued at -0.88, compared to the broader market0.002.004.006.00-0.882.92
The chart of Martin ratio for EDIT, currently valued at -1.28, compared to the broader market-10.000.0010.0020.0030.00-1.2813.38
EDIT
SPYI

The current EDIT Sharpe Ratio is -1.04, which is lower than the SPYI Sharpe Ratio of 1.94. The chart below compares the historical Sharpe Ratios of EDIT and SPYI, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00SeptemberOctoberNovemberDecember2025February
-1.04
1.94
EDIT
SPYI

Dividends

EDIT vs. SPYI - Dividend Comparison

EDIT has not paid dividends to shareholders, while SPYI's dividend yield for the trailing twelve months is around 11.77%.


TTM202420232022
EDIT
Editas Medicine, Inc.
0.00%0.00%0.00%0.00%
SPYI
NEOS S&P 500 High Income ETF
11.77%12.04%12.01%4.10%

Drawdowns

EDIT vs. SPYI - Drawdown Comparison

The maximum EDIT drawdown since its inception was -98.74%, which is greater than SPYI's maximum drawdown of -10.19%. Use the drawdown chart below to compare losses from any high point for EDIT and SPYI. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-91.48%
0
EDIT
SPYI

Volatility

EDIT vs. SPYI - Volatility Comparison

Editas Medicine, Inc. (EDIT) has a higher volatility of 21.78% compared to NEOS S&P 500 High Income ETF (SPYI) at 2.10%. This indicates that EDIT's price experiences larger fluctuations and is considered to be riskier than SPYI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%SeptemberOctoberNovemberDecember2025February
21.78%
2.10%
EDIT
SPYI
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab